Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery

Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery (MAGIPAC): A Randomized Clinical Trial.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05428358

Acronym

MAGIPAC

Enrollment

200

Registered

2022-06-23

Start date

2022-08-30

Completion date

2028-12-01

Last updated

2026-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Metastases, Pancreatic Cancer, Pancreatic Neoplasm

Keywords

magnetic resonance imaging

Brief summary

The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients.

Detailed description

The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients. We will conduct a nationwide, prospective clinical trial to examine the incremental value of using MRI for identification of liver metastases in pancreatic cancer patients.

Interventions

DIAGNOSTIC_TESTPreoperative MRI

Preoperative MRI performed between outpatient visit at the surgical clinic and scheduled date of resection

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

* Pancreatic cancer patients considered to have a locally resectable or borderline resectable tumor by the local hepato-pancreato-biliary multidisciplinary team board * No liver metastases on CT * At least 18 years old and able to provide informed consent * Expected pancreatic ductal adenocarcinoma based on CT scan

Exclusion criteria

* Metastatic disease * Prior receipt of neoadjuvant chemotherapy or downstaging/-sizing treatment * Comorbidity rendering major surgery unfeasible (inoperable) * No informed consent * Unable to undergo MRI (Kidney insufficiency (eGFR \< 60 ml/min/1.73 m2 body surface ar-ea); Claustrophobia; Cardiac pacemaker) * Postoperative histology other than adenocarcinoma of pancreato-biliary origin. * MRI with liver-specific contrast performed during standard workup.

Design outcomes

Primary

Measure	Time frame	Description
Change in treatment strategy	1 week	Change in treatment strategy from intended curative resection to other treatment based on MRI scan

Secondary

Measure	Time frame	Description
Liver metastases	1 week	Proportion of patients who had liver metastases detected on MRI
Surgery	1 month	Proportion of patients who made it to surgery/exploration
Resection	1 month	Proportion of patients in each arm who had a pancreatic resection performed
Intraoperatively detected liver metastases	1 month	Proportion of patients with intraoperatively detected liver metastases not seen on either CT or MRI.
Overall survival (1-year)	1 year	1-year overall survival.
Overall survival (3-year)	3 years	3-year overall survival.
Recurrence-free survival	3 years	Recurrence-free survival according to final treatment strategy.
Healthcare costs	3 years	Healthcare costs in patients with change of treatment.

Countries

Denmark

Contacts

CONTACTJakob Kirkegård, MD, PhD

jakob.kirkegaard@auh.rm.dk+4522900604

CONTACTFrank Mortensen, MD, DMSc

frmort@rm.dk+45222517296

STUDY_CHAIRFrank Mortensen, MD, DMSc

Aarhus University Hospital

PRINCIPAL_INVESTIGATORJakob Kirkegård, MD, PhD